Edgestream Partners, L.P. Tg Therapeutics, Inc. Transaction History
Edgestream Partners, L.P.
- $2.88 Billion
- Q1 2025
A detailed history of Edgestream Partners, L.P. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 65,249 shares of TGTX stock, worth $2.56 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
65,249
Previous 53,738
21.42%
Holding current value
$2.56 Million
Previous $1.62 Million
59.06%
% of portfolio
0.09%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding TGTX
# of Institutions
416Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$613 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$448 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$292 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$129 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$112 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.71B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...